Investor Alert: ADMA Biologics Securities Fraud Investigation After 29% Stock Decline
Overview: Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) have incurred significant losses after a sharp stock decline linked to allegations of securities fraud related to revenue reporting. Background ADMA Biologics is currently under investigation by multiple law firms for potential violations of federal securities laws. (https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adma-biologics-inc---adma-302737867.html) The investigation focuses on whether the company and its [...]




